Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient

Pembrolizumab is an immune checkpoint inhibitor that induces side effects called “immune‐related adverse events” (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Onuki, Tsugitoshi, Morita, Eri, Sakamoto, Noritaka, Nagai, Yoshiaki, Sata, Masafumi, Hagiwara, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980602/
https://www.ncbi.nlm.nih.gov/pubmed/30065841
http://dx.doi.org/10.1002/rcr2.334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980602/
https://www.ncbi.nlm.nih.gov/pubmed/30065841
http://dx.doi.org/10.1002/rcr2.334

Ejemplares similares